Intellia Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · 40 ERIE STREET, SUITE 130, CAMBRIDGE, MA 02139
官方登記資料
0位追蹤者
2014成立於
關於 Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Source: Wikipedia
產業In Vitro & In Vivo Diagnostic Substances
總部40 ERIE STREET, SUITE 130, CAMBRIDGE, MA 02139
成立時間2014
法律形式C Corporation
狀態營運中
專利616 項專利
METHODS FOR IN VIVO EDITING OF KLKB1US20260240959A1 · 2026
IONIZABLE AMINE LIPIDSUS20260225997A1 · 2026
關鍵數據
法律資訊
| 法定名稱 | Intellia Therapeutics, Inc. |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 1652130在 SEC EDGAR 上查看 ↗ |
| EIN | 36-4785571 |
| 產業代碼(SIC) | 2835 |
| 登記地址 | 40 ERIE STREET, SUITE 130, CAMBRIDGE, MA 02139 |
| 狀態 | 營運中 |
來源: SEC EDGAR · 更新於 2026年10月15日
聯絡方式與連結
地點
40 ERIE STREET, SUITE 130, CAMBRIDGE, MA 02139
這是你的公司嗎?
免費認領此頁面,即可新增標誌、產品、照片與職缺,並回覆評論。
認領此頁面